Innoen 10% Hura Basol Injection

Adult administration

Administer by intravenous drip as a maximum dosage of 1 to 1.5 g of total amino acids per kg of body weight per day. Administer 1 mL/kg intravenously per day for adults, with a maximum dose of 20 mL/kg. The infusion rate should be approximately 10 g of total amino acids over 60 minutes, typically administered as 25-30 drops per minute.

Child administration

For children, the dosage and infusion rate should be appropriately adjusted.

This drug must be used strictly according to a doctor's instructions. Patients with hepatic coma or at risk of hepatic coma, severe renal impairment or hyperazotemia, metabolic disorders affecting nitrogen utilization, wasting heart failure, pulmonary edema, patients with very little or no urine output should not be administered this medication. In addition, patients with hypernatremia or hyperchloremia, and alkalosis if sodium and chloride ions are included, patients with complete heart block or myasthenia gravis if magnesium ions are present, patients at risk of fluid overload, life-threatening circulatory failure, patients with inadequate cellular oxygen supply, infants under 2 years old, and patients with a history of myocardial infarction should also not use this medication. Caution should be exercised when administering to patients with severe acidosis, congestive heart failure, hepatic or renal impairment, or those with edema due to sodium retention (if sodium ions are included), and in patients with hyperkalemia or potassium retention (if potassium ions are included). Rarely, hypersensitivity reactions like rash may occur, in which case administration should be stopped immediately. Symptoms of the digestive system like nausea and vomiting, discomfort in the chest, palpitations, rapid pulse, and elevated blood pressure may also develop. Rapid large volume administration may lead to acidosis, so caution is advised. Occasionally, chills, fever, headache, difficulty breathing, respiratory arrest, shock, bronchospasm, and urinary spasm may occur. Metabolic complications such as metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, dehydration, rebound hypoglycemia, elevated liver enzymes, vitamin deficiency or excess, electrolyte imbalance, and hyperammonemia in children may arise. In patients with hepatic or renal dysfunction, blood urea nitrogen (BUN) levels may rise. Patients with liver failure may experience symptoms such as serum amino acid imbalance, metabolic alkalosis, systemic nitrogen blood rise, hyperammonemia, or coma, hence careful monitoring is necessary. When administered in large doses or alongside electrolyte solutions, attention must be paid to electrolyte balance, and exceeding the dosage may lead to metabolic alkalosis; therefore, caution is necessary when using formulations containing acetate ions. Patients with histories of kidney disease, pulmonary disease, or cardiovascular disease should be careful to avoid fluid overload. Diabetic patients should frequently check their blood sugar levels while using this medication. Caution must be taken regarding interactions when used with other drugs. For example, administering it concurrently with tetracycline may reduce the amino acid's protein-sparing effect, and if magnesium ions are present, precipitation may occur when used with calcium salts. The safety for pregnant women is not established, so it should only be administered if the therapeutic benefits outweigh the risks. It is advisable to use specially formulated amino acid products for neonates, infants, and children. Elderly patients require caution, as their physiological function often declines, and administration rates should be adjusted to be slower and doses reduced. During administration, attention must be given to electrolyte balance depending on the presence of electrolytes; rapid infusion may cause chills or vomiting, and loss of amino acids through the kidneys may increase, thus it should be administered slowly. The injection should be used at approximately body temperature, prepared in a sterile manner, and all syringe equipment should be thoroughly sterilized to reduce the risk of infection. Do not use if residual solution or an opaque solution is present, and use quickly after mixing with other solutions, ensuring to use within 24 hours if refrigerated. If crystallization occurs, heat to 50-60 degrees Celsius to dissolve and then cool to about body temperature before use. Store in a sealed container to avoid air or moisture exposure and it is preferable to keep it at room temperature, away from direct sunlight, to maintain the drug's efficacy for a longer duration.

Serious side effects

• Difficulty breathing
• respiratory arrest
• shock
• bronchospasm
• hepatic failure
• renal failure.

Mild side effects

Rash, nausea, vomiting, chest discomfort, palpitations, rapid pulse (tachycardia), elevated blood pressure, acidosis, chills, fever, headache, urinary spasm, metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, osmotically induced diuresis and dehydration, rebound hypoglycemia, elevated liver enzymes, vitamin deficiency and excess, electrolyte imbalance, hyperammonemia in children, elevated BUN, serum amino acid imbalance, metabolic alkalosis, systemic nitrogen blood rise.

This medication should be stored in a sealed container to prevent air or moisture access, and it is recommended to keep it at room temperature away from direct sunlight. This will help maintain the drug's efficacy for a long time.

Appearance

A colorless or pale yellow, transparent injection solution filled in a colorless transparent plastic container.

Package unit

250, 500 milliliters